Ameriprise
LEGN icon

Ameriprise’s Legend Biotech LEGN Stock Holding History

Ameriprise’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.36M Buy
75,439
+377
+0.5% +$7.19K ﹤0.01% 3151
2025
Q4 		$1.63M Sell
75,062
-467,260
-86% -$13.4M ﹤0.01% 3106
2025
Q3 		$17.7M Sell
542,322
-85,863
-14% -$3.17M ﹤0.01% 1494
2025
Q2 		$22.3M Sell
628,185
-28,963
-4% -$939K 0.01% 1276
2025
Q1 		$22.3M Sell
657,148
-109,292
-14% -$3.92M 0.01% 1239
2024
Q4 		$24.9M Buy
766,440
+52,939
+7% +$2.19M 0.01% 1195
2024
Q3 		$34.8M Buy
713,501
+56,114
+9% +$2.99M 0.01% 1032
2024
Q2 		$29.1M Buy
657,387
+563,668
+601% +$26M 0.01% 1053
2024
Q1 		$5.26M Sell
93,719
-4,169
-4% -$251K ﹤0.01% 2333
2023
Q4 		$5.89M Buy
97,888
+41,741
+74% +$2.65M ﹤0.01% 2226
2023
Q3 		$3.77M Buy
56,147
+19,889
+55% +$1.38M ﹤0.01% 2495
2023
Q2 		$2.5M Buy
+36,258
New +$2.37M ﹤0.01% 2767
2023
Q1 		– Sell
-241,150
Closed -$12M – 3996
2022
Q4 		$12M Sell
241,150
-59,446
-20% -$2.88M ﹤0.01% 1589
2022
Q3 		$12.3M Buy
+300,596
New +$14.1M ﹤0.01% 1508

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Ameriprise's LEGN Position: Q1 2026 in Review

Ameriprise increased its Legend Biotech (LEGN) stake by 0.5% in Q1 2026, buying an estimated $7.19K and bringing the position to 75,439 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3151.

Ameriprise first reported a position in LEGN in Q3 2022 and has held it in 14 quarters since. The position peaked at $34.8M in Q3 2024. 189 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Ameriprise held 75,439 shares of Legend Biotech worth $1.36M as of Q1 2026.
  • Ameriprise bought 377 Legend Biotech shares in Q1 2026, an estimated $7.19K.
  • Legend Biotech made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3151 holding.
  • Ameriprise first reported a position in Legend Biotech in Q3 2022 and has held it in 14 quarters since.
  • Ameriprise's Legend Biotech position peaked at $34.8M in Q3 2024.
  • 189 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.